<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03560557</url>
  </required_header>
  <id_info>
    <org_study_id>ML8459</org_study_id>
    <nct_id>NCT03560557</nct_id>
  </id_info>
  <brief_title>Optimization of PK/PD Target Attainment for Meropenem in Critically Ill Patients With Sepsis</brief_title>
  <official_title>Optimization of PK/PD Target Attainment for Meropenem in Critically Ill Patients With Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      WP1.1. PK/PD target attainment: Plasma exposure, Excretion via urine &amp; ELF exposure; WP1.2.
      Predictive dosing algorithm; WP1.3. ECMO subset
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      First, the investigators will document exposure to meropenem in plasma and epithelial lining
      fluid. Moreover excretion in urine will be documented.

      Second, the investigators will try to identify risk factors for not attaining PK/PD target.
      Based on significant predictors for target non attainment a predictive dosing algorithm will
      be constructed.

      Finally in a small subset of ECMO patients PK exposure will be explored.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2012</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Risk factors for target non attainment</measure>
    <time_frame>on day of sampling</time_frame>
    <description>risk factors will be assessed by comparing patients who attain target vs. those who don't</description>
  </primary_outcome>
  <enrollment type="Actual">116</enrollment>
  <condition>Critical Illness</condition>
  <condition>Pharmacokinetics</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, serum, urine, bronchoalveolar lavage fluid
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Critically ill patients with sepsis and receiving meropenem
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe sepsis or septic shock

          -  Admitted to an ICU ward

          -  Treated with meropenem

        Exclusion Criteria:

          -  eGFR(CKD-EPI) &lt; 70ml/min/1.73mÂ²

          -  Renal replacement therapy

          -  Pregnancy

          -  DNR code 1-3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabel Spriet, PharmD PhD</last_name>
    <role>Study Director</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 6, 2018</study_first_submitted>
  <study_first_submitted_qc>June 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>May 3, 2019</last_update_submitted>
  <last_update_submitted_qc>May 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Matthias Gijsen</investigator_full_name>
    <investigator_title>PharmD</investigator_title>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Meropenem</keyword>
  <keyword>Critical illness</keyword>
  <keyword>Capillary leak</keyword>
  <keyword>Augmented renal clearance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>To be discussed</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

